GGrantIndex
Sort

53,477 grants matching addiction

Mouse models of stress disorders and addiction

$3,074,342
Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2023 · AA

Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain

$3,072,761
James N Campbell · Centrexion Therapeutics Corporation · UH3 · FY2023 · NS

Evaluating New Nicotine Standards for Cigarettes

$3,072,358
Eric Christian Donny · University Of Pittsburgh At Pittsburgh · U54 · FY2013 · DA

Associative learning, decision-making, and addiction

$3,071,494
Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2015 · DA

Procurement and Characterization of Postmortem Brain Tissue

$3,068,293
Karen Faith Berman · National Institute Of Mental Health · ZIC · FY2013 · MH

Neural circuit dynamics of drug action

$3,065,324
Karl Alexander Deisseroth · Stanford University · P50 · FY2019 · DA

Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers

$3,064,047
Nicholas David Cosford · Sanford Burnham Prebys Medical Discovery Institute · U01 · FY2023 · DA

HEALTH Center for Addictions Research and Cancer Prevention

$3,061,961
Bettina M Beech · University Of Houston · U54 · FY2023 · MD

Development of a novel drug for treating opioid use disorder

$3,060,540
Nikej Shah · Nirsum Laboratories, Inc. · UG3 · FY2019 · DA

Development of a novel drug for treating opioid use disorder

$3,058,678
Nikej Shah · Nirsum Laboratories, Inc. · UG3 · FY2020 · DA

Development of a novel drug for treating opioid use disorder

$3,056,516
Nikej Shah · Nirsum Laboratories, Inc. · UH3 · FY2022 · DA

TREATMENT OF ADDICTIONS-BIOLOGICAL CORRELATES

$3,056,419
Mary J Kreek · Rockefeller University · P60 · FY2010 · DA

Development of a novel drug for treating opioid use disorder

$3,052,891
Nikej Shah · Nirsum Laboratories, Inc. · UH3 · FY2023 · DA

Development of a novel drug for treating opioid use disorder

$3,051,459
Nikej Shah · Nirsum Laboratories, Inc. · UH3 · FY2024 · DA

TREATMENT OF ADDICTIONS--BIOLOGICAL CORRELATES

$3,048,429
Mary J Kreek · Rockefeller University · P60 · FY2006 · DA

Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics

$3,046,519
Alan R Buckpitt · Eicosis, Llc · UG3 · FY2020 · DA

Microdialysis Studies of Self-administrationx

$3,043,950
Roy A Wise · National Institute On Drug Abuse · Z01 · FY2008 · DA

TREATMENT OF ADDICTIONS-BIOLOGICAL CORRELATES

$3,043,511
Mary J Kreek · Rockefeller University · P60 · FY2011 · DA

Characterization of neuronal ensembles activated during cue-induced reward seeking

$3,042,644
Bruce Hope · National Institute On Drug Abuse · ZIA · FY2023 · DA

Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics

$3,036,135
Alan R Buckpitt · Eicosis, Llc · UG3 · FY2019 · DA

A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.

$3,032,676
Fiona J. Thomson · Astrazeneca Pharmaceuticals, Lp · UG3 · FY2021 · DA

Biobehavioral Imaging and Molecular Neuropsychopharmacology of Substance Abuse Mechanisms

$3,032,457
Michael Michaelides · National Institute On Drug Abuse · ZIA · FY2023 · DA

A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder

$3,027,897
Paul J Kenny · Eolas Therapeutics, Inc. · UH3 · FY2025 · DA

JCOIN Coordination and Translation Center

$3,026,100
Faye S Taxman · George Mason University · U2C · FY2022 · DA

Healthy Brain and Child Development National Consortium Data Coordinating Center

$3,025,233
Christopher Daniel Smyser · Washington University · U24 · FY2024 · DA